Rise and Fall of Anti-obesity Drugs

Overview

Journal World J Diabetes

Publisher Baishideng Publishing Group

Specialty Endocrinology

Date 2011 May 4

PMID 21537456

Citations 29

Authors

Ming-Fang Li

Bernard My Cheung

Affiliations

Soon will be listed here.

Abstract

Although it is not generally a life-threatening disease, obesity is becoming a major health problem worldwide. It can be controlled by means of drugs, and, consequently, these are required to be safe as well as effective. In this paper, we summarize the fate of various drugs that have been introduced for clinical use in the treatment of obesity. Fenfluramine and dexfenfluramine were withdrawn because of heart valve damage. Sibutramine suppresses appetite and increases heart rate and blood pressure. In the Sibutramine Cardiovascular OUTcomes trial, an increase in major adverse cardiovascular events prompted its withdrawal in Europe and the United States. Rimonabant is an endocannabinoid receptor antagonist that reduces body weight and ameliorates some cardiovascular risk factors. However, adverse psychiatric side effects led to its withdrawal as well. Orlistat is approved in Europe and the United States for the treatment of obesity, but its use is limited by gastrointestinal side-effects. Ephedrine and caffeine are natural ingredients in foods and supplements that may help the person to lose weight. In the light of several failed attempts, there is a clear need to develop drugs that are effective and safe in the long term in order to successfully combat the phenomenon of obesity .

Citing Articles

Chirality of New Drug Approvals (2013-2022): Trends and Perspectives.

McVicker R, OBoyle N J Med Chem. 2024; 67(4):2305-2320.

PMID: 38344815 PMC: 10895675. DOI: 10.1021/acs.jmedchem.3c02239.

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.

Rouaud A, Calder A, Hasler G J Psychopharmacol. 2024; 38(3):217-224.

PMID: 38214279 PMC: 10944580. DOI: 10.1177/02698811231225609.

Acupuncture as multi-targeted therapy for the multifactorial disease obesity: a complex neuro-endocrine-immune interplay.

Landgraaf R, Bloem M, Fumagalli M, Benninga M, de Lorijn F, Nieuwdorp M Front Endocrinol (Lausanne). 2023; 14:1236370.

PMID: 37795371 PMC: 10545882. DOI: 10.3389/fendo.2023.1236370.

360-Degree Perspectives on Obesity.

Cuciureanu M, Caratasu C, Gabrielian L, Frasinariu O, Checherita L, Trandafir L Medicina (Kaunas). 2023; 59(6).

PMID: 37374323 PMC: 10304508. DOI: 10.3390/medicina59061119.

Tea Plant (): A Current Update on Use in Diabetes, Obesity, and Cardiovascular Disease.

Brimson J, Prasanth M, Kumaree K, Thitilertdecha P, Malar D, Tencomnao T Nutrients. 2023; 15(1).

PMID: 36615695 PMC: 9823498. DOI: 10.3390/nu15010037.

References

Nisoli E, Carruba M . A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf. 2003; 26(14):1027-48. DOI: 10.2165/00002018-200326140-00004. View

Pagotto U, Pasquali R . Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005; 365(9468):1363-4. DOI: 10.1016/S0140-6736(05)66348-9. View

Samaha F, Iqbal N, Seshadri P, Chicano K, Daily D, McGrory J . A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003; 348(21):2074-81. DOI: 10.1056/NEJMoa022637. View

Maahs D, de Serna D, Kolotkin R, Ralston S, Sandate J, Qualls C . Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006; 12(1):18-28. DOI: 10.4158/EP.12.1.18. View

Nakou E, Filippatos T, Liberopoulos E, Tselepis A, Kiortsis D, Mikhailidis D . Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother. 2008; 9(10):1629-39. DOI: 10.1517/14656566.9.10.1629. View

Pi-Sunyer F, Aronne L, Heshmati H, Devin J, Rosenstock J . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006; 295(7):761-75. DOI: 10.1001/jama.295.7.761. View

Bravata D, Sanders L, Huang J, Krumholz H, Olkin I, Gardner C . Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA. 2003; 289(14):1837-50. DOI: 10.1001/jama.289.14.1837. View

Schneider R, Golzman B, Turkot S, Kogan J, Oren S . Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci. 2005; 330(4):157-60. DOI: 10.1097/00000441-200510000-00001. View

Serrano-Rios M, Melchionda N . Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med. 2002; 19(2):119-24. DOI: 10.1046/j.1464-5491.2002.00655.x. View

10.

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

11.

James W, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A . Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10):905-17. DOI: 10.1056/NEJMoa1003114. View

12.

Mokdad A, Ford E, Bowman B, Dietz W, Vinicor F, Bales V . Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2002; 289(1):76-9. DOI: 10.1001/jama.289.1.76. View

13.

Jones D . Novel pharmacotherapies for obesity poised to enter market. Nat Rev Drug Discov. 2009; 8(11):833-4. DOI: 10.1038/nrd3044. View

14.

Shi Y, Pan C, Hill J, Gao Y . Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2006; 22(12):1737-43. DOI: 10.1111/j.1464-5491.2005.01723.x. View

15.

Di Marzo V, Bifulco M, De Petrocellis L . The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004; 3(9):771-84. DOI: 10.1038/nrd1495. View

16.

Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A . A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord. 2000; 24(2):144-50. DOI: 10.1038/sj.ijo.0801098. View

17.

Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N . Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006; 79(5):500-8. DOI: 10.1016/j.clpt.2006.02.002. View

18.

McNeely W, Goa K . Sibutramine. A review of its contribution to the management of obesity. Drugs. 1999; 56(6):1093-124. DOI: 10.2165/00003495-199856060-00019. View

19.

Bray G . Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med. 1993; 119(7 Pt 2):707-13. DOI: 10.7326/0003-4819-119-7_part_2-199310011-00016. View

20.

Hu F, Manson J, Stampfer M, Colditz G, Liu S, Solomon C . Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001; 345(11):790-7. DOI: 10.1056/NEJMoa010492. View